Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma

Hamilton, 2006, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br J Cancer, 94, 642, 10.1038/sj.bjc.6603012 Han, 2021, Clinicopathological characteristics and prognosis of uterine serous carcinoma: A SEER program analysis of 1016 cases, J Obstet Gynaecol Res, 47, 2460, 10.1111/jog.14797 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Davis, 2019, The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors, J Immunother Cancer, 7, 278, 10.1186/s40425-019-0768-9 Arora, 2020, FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis, Clin Cancer Res, 26, 5062, 10.1158/1078-0432.CCR-19-3979 Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med386, 437–448. https://doi.org/10.1056/NEJMoa2108330 (2022). Sloan, 2017, PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors, Am J Surg Pathol, 41, 326, 10.1097/PAS.0000000000000783 Yamashita, 2018, Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer, Oncotarget, 9, 5652, 10.18632/oncotarget.23790 Li, 2018, Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency, Int J Gynecol Cancer, 28, 59, 10.1097/IGC.0000000000001120 Kim, 2018, Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer, Gynecol Oncol, 149, 381, 10.1016/j.ygyno.2018.02.013 Kucukgoz Gulec, 2019, Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer, Arch Gynecol Obstet, 300, 377, 10.1007/s00404-019-05180-2 Talhouk, 2019, Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma, Clin Cancer Res, 25, 2537, 10.1158/1078-0432.CCR-18-3241 Pasanen, 2020, PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups, Am J Surg Pathol, 44, 174, 10.1097/PAS.0000000000001395 Zong, 2021, PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer, Gynecol Oncol, 162, 631, 10.1016/j.ygyno.2021.07.009 Amarin JZ, Mansour R, Al-Ghnimat S & Al-Hussaini M. Differential Characteristics and Prognosis of PD-L1-Positive Endometrial Carcinomas: A Retrospective Chart Review. Life(Basel)11 (2021). Zhang, 2021, PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance, Cancer Manag Res, 13, 9157, 10.2147/CMAR.S337271 Koyama, 2016, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat Commun, 7, 10501, 10.1038/ncomms10501 Hellmann, 2016, Combinatorial Cancer Immunotherapies, Adv Immunol, 130, 251, 10.1016/bs.ai.2015.12.005 Dempke, 2017, Second- and third-generation drugs for immuno-oncology treatment-The more the better?, Eur J Cancer, 74, 55, 10.1016/j.ejca.2017.01.001 Qin, 2020, Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation, Front Oncol, 10, 1288, 10.3389/fonc.2020.01288 Anderson, 2007, Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells, Science, 318, 1141, 10.1126/science.1148536 Hastings, 2009, TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines, Eur J Immunol, 39, 2492, 10.1002/eji.200939274 Monney, 2002, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, 415, 536, 10.1038/415536a Chapoval, 2001, B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production, Nat Immunol, 2, 269, 10.1038/85339 Liu, 2021, The Role of CD276 in Cancers, Front Oncol, 11 Tian, 2021, Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade, Front Oncol, 11, 10.3389/fonc.2021.731175 Zhou, 2021, B7-H3/CD276: An Emerging Cancer Immunotherapy, Front Immunol, 12 Wang, 2017, Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis, Medicine (Baltimore), 96, e6369, 10.1097/MD.0000000000006369 Zang, 2021, TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation, Front Oncol, 11, 10.3389/fonc.2021.579351 Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F et al. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunol Immunother71, 1549–1567. https://doi.org/10.1007/s00262-021-03097-x (2022). Loos, 2010, B7-h3 and its role in antitumor immunity, Clin Dev Immunol, 2010, 10.1155/2010/683875 Howitt, 2015, Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1, JAMA Oncol, 1, 1319, 10.1001/jamaoncol.2015.2151 Eggink, 2017, Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition, Oncoimmunology, 6, 10.1080/2162402X.2016.1264565 Mo, 2016, Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer, Oncol Lett, 12, 944, 10.3892/ol.2016.4744 Bregar, 2017, Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors, Gynecol Oncol, 145, 446, 10.1016/j.ygyno.2017.03.006 Asaka, 2019, T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers, Mod Pathol, 32, 576, 10.1038/s41379-018-0172-x Engerud, 2020, High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer, Gynecol Oncol, 157, 260, 10.1016/j.ygyno.2020.01.020 Kir, 2020, Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas, Virchows Arch, 477, 845, 10.1007/s00428-020-02867-9 Vagios, 2019, The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas, Int J Clin Oncol, 24, 1419, 10.1007/s10147-019-01484-0 Kondratiev, 2004, Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma, Clin Cancer Res, 10, 4450, 10.1158/1078-0432.CCR-0732-3 de Jong, 2009, Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer, Gynecol Oncol, 114, 105, 10.1016/j.ygyno.2009.03.022 Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 10.1126/scitranslmed.3003689 Teng, 2015, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res, 75, 2139, 10.1158/0008-5472.CAN-15-0255 Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat Immunol, 14, 1014, 10.1038/ni.2703 Moore, 2019, TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers, Mod Pathol, 32, 1168, 10.1038/s41379-019-0251-7 Ramos, 2018, Checkpoint inhibitor signatures across endometrial carcinoma histologic subtypes, Gynecol Oncol, 149, 621, 10.1016/j.ygyno.2018.03.012 Brunner, 2012, Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis, Gynecol Oncol, 124, 105, 10.1016/j.ygyno.2011.09.012 Nishimura, 2018, PD-L1 and B7-H3 expression in serous carcinoma of endometrium, Cancer Research, 10.1158/1538-7445.AM2018-4566 Shayan, 2016, Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer, Oncoimmunology, 6 Acharya, 2020, Tim-3 finds its place in the cancer immunotherapy landscape, Journal for immunotherapy of cancer, 8, 10.1136/jitc-2020-000911 Yonesaka, 2018, B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity, Clin Cancer Res, 24, 2653, 10.1158/1078-0432.CCR-17-2852 Victoor, 2021, Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study, Gynecol Oncol, 162, 694, 10.1016/j.ygyno.2021.06.030 Murali, 2014, Classification of endometrial carcinoma: more than two types, Lancet Oncol, 15, e268, 10.1016/S1470-2045(13)70591-6